GlaxoSmithKline launch herpes vaccine

GlaxoSmithKline PLC's experimental genital herpes vaccine will begin new clinical trials on female subjects, GSK and the National Institutes of Health said.

The prototype for the vaccine, to treat the herpes simplex virus types HSV-1 and HSV-2, will be tested in a phase III trial on 7,550 women who are not carriers of the virus, but whose partners are infected.